Bradykinin receptor participates in doxorubicin‐induced cardiotoxicity by modulating iNOS signal pathway
Journal of Biochemical and Molecular Toxicology · 2023
DOI: 10.1002/jbt.23393 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Biochemical and Molecular Toxicology, 2023. Verfasst von Xueyan Chen und 5 weiteren Autor:innen. Beteiligte Einrichtung: The Key Laboratory of Neural and Vascular Biology, Ministry of Education, Hebei Medical University, Shijiazhuang, P. R. China. Hauptthemen laut MEDLINE: Cardiotoxicity, Heart Injuries. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 42 Literaturangaben. Gefördert von: Natural Science Foundation of China, Key projects planned by Hebei administration of traditional Chinese Medicine, Natural science foundation of Hebei Province.
Abstract (Originalsprache)
Doxorubicin (DOX), an effective and broad‐spectrum anthracycline antibiotic, is widely used in the treatment of numerous malignancies. However, dose‐dependent cardiotoxicity limits the clinical application of DOX, and the molecular mechanisms are still unknown. In this study, we used the BK receptor B1/B2 double‐knockout (B1B 2 ‐/‐ ) mice to observe the role of BK receptor in cardiotoxicity induced by DOX and the underlying mechanisms. DOX induced myocardial injury with increased serum levels of AST, CK, and LDH, upregulated tissue expression of bradykinin B1/B2 receptor, FABP4 and iNOS, and downregulated expression of eNOS. However, these altered releases of myocardial enzyme and the expression level of iNOS were significantly prevented in the B1B2 ‐/‐ mice. We concluded that the activation of both B1 and B2 receptors of BK were involved in the DOX‐induced acute myocardial injury, possibly mediated through iNOS signaling pathways.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- The Key Laboratory of Neural and Vascular Biology, Ministry of Education, Hebei Medical University, Shijiazhuang, P. R. China.
- Department of Pharmacology, The Key Laboratory of Pharmacology and Toxicology for New Drugs, Hebei Medical University, Shijiazhuang, P. R. China.
- Department of Pharmacy, Shijiazhuang people's hospital, Shijiazhuang, P. R. China.
- Department of Cardiology, The Second Hospital of Hebei Medical University Shijiazhuang, Shijiazhuang, China.
- State Key Laboratory of Radiation Medicine and Prevention, Cyrus Tang Hematology Center, Collaborative Innovation Center of Hematology, National Clinical Research Center for Hematologic Diseases, The First Affiliated Ho…
Förderung
- Natural Science Foundation of China
- Key projects planned by Hebei administration of traditional Chinese Medicine
- Natural science foundation of Hebei Province
- National Science foundation of Hebei Province
Zitieren
APA
Chen, X., Xie, K., Zhang, X., Gu, X., Wu, Y., & Su, S. (2023). Bradykinin receptor participates in doxorubicin‐induced cardiotoxicity by modulating iNOS signal pathway. Journal of Biochemical and Molecular Toxicology. https://doi.org/10.1002/jbt.23393
Vancouver
Chen X, Xie K, Zhang X, Gu X, Wu Y, Su S. Bradykinin receptor participates in doxorubicin‐induced cardiotoxicity by modulating iNOS signal pathway. Journal of Biochemical and Molecular Toxicology. 2023. doi:10.1002/jbt.23393
BibTeX
@article{Chen2023,
author = {Chen, Xueyan and Xie, Kerang and Zhang, Xiaofei and Gu, Xinshun and Wu, Yi and Su, Suwen},
title = {Bradykinin receptor participates in doxorubicin‐induced cardiotoxicity by modulating iNOS signal pathway},
journal = {Journal of Biochemical and Molecular Toxicology},
year = {2023},
doi = {10.1002/jbt.23393}
}
EUVIMED